vs
渤健（BIIB）与RUSH ENTERPRISES INC \TX\（RUSHA）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是RUSH ENTERPRISES INC \TX\的1.5倍（$2.5B vs $1.7B），渤健净利率更高（12.9% vs 3.7%，领先9.2%），渤健同比增速更快（2.0% vs -9.0%），渤健自由现金流更多（$594.3M vs $411.6M），过去两年渤健的营收复合增速更高（0.3% vs -6.8%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Rush Enterprises是总部位于美国得克萨斯州新布朗费尔斯的商用车经销商，核心业务是通过旗下Rush Truck Centers销售全新及二手卡车。2019年该公司在全美20个州运营超200家卡车中心，在加拿大设有14个网点，2020年入选财富500强榜单。
BIIB vs RUSHA — 直观对比
营收规模更大
BIIB
是对方的1.5倍
$1.7B
营收增速更快
BIIB
高出11.0%
-9.0%
净利率更高
BIIB
高出9.2%
3.7%
自由现金流更多
BIIB
多$182.7M
$411.6M
两年增速更快
BIIB
近两年复合增速
-6.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $1.7B |
| 净利润 | $319.5M | $61.7M |
| 毛利率 | — | 20.4% |
| 营业利润率 | — | 4.9% |
| 净利率 | 12.9% | 3.7% |
| 营收同比 | 2.0% | -9.0% |
| 净利润同比 | 32.8% | 1.8% |
| 每股收益（稀释后） | $2.15 | $0.77 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBRUSHA
| Q1 26 | $2.5B | $1.7B | ||
| Q4 25 | $2.3B | $1.7B | ||
| Q3 25 | $2.5B | $1.8B | ||
| Q2 25 | $2.6B | $1.8B | ||
| Q1 25 | $2.4B | $1.8B | ||
| Q4 24 | $2.5B | $1.9B | ||
| Q3 24 | $2.5B | $1.8B | ||
| Q2 24 | $2.5B | $1.9B |
净利润BIIBRUSHA
| Q1 26 | $319.5M | $61.7M | ||
| Q4 25 | $-48.9M | $64.3M | ||
| Q3 25 | $466.5M | $66.7M | ||
| Q2 25 | $634.8M | $72.4M | ||
| Q1 25 | $240.5M | $60.3M | ||
| Q4 24 | $266.7M | $74.8M | ||
| Q3 24 | $388.5M | $79.1M | ||
| Q2 24 | $583.6M | $78.7M |
毛利率BIIBRUSHA
| Q1 26 | — | 20.4% | ||
| Q4 25 | 78.3% | 20.8% | ||
| Q3 25 | 73.4% | 21.0% | ||
| Q2 25 | 77.1% | 20.7% | ||
| Q1 25 | 74.1% | 20.3% | ||
| Q4 24 | 76.2% | 19.3% | ||
| Q3 24 | 74.1% | 21.0% | ||
| Q2 24 | 77.8% | 20.2% |
营业利润率BIIBRUSHA
| Q1 26 | — | 4.9% | ||
| Q4 25 | -2.5% | 5.5% | ||
| Q3 25 | 22.0% | 5.6% | ||
| Q2 25 | 28.1% | 6.0% | ||
| Q1 25 | 12.8% | 5.2% | ||
| Q4 24 | 11.9% | 5.8% | ||
| Q3 24 | 18.3% | 6.7% | ||
| Q2 24 | 28.3% | 6.4% |
净利率BIIBRUSHA
| Q1 26 | 12.9% | 3.7% | ||
| Q4 25 | -2.1% | 3.8% | ||
| Q3 25 | 18.4% | 3.7% | ||
| Q2 25 | 24.0% | 3.9% | ||
| Q1 25 | 9.9% | 3.4% | ||
| Q4 24 | 10.9% | 3.9% | ||
| Q3 24 | 15.8% | 4.4% | ||
| Q2 24 | 23.7% | 4.1% |
每股收益（稀释后）BIIBRUSHA
| Q1 26 | $2.15 | $0.77 | ||
| Q4 25 | $-0.35 | $0.81 | ||
| Q3 25 | $3.17 | $0.83 | ||
| Q2 25 | $4.33 | $0.90 | ||
| Q1 25 | $1.64 | $0.73 | ||
| Q4 24 | $1.82 | $-95.13 | ||
| Q3 24 | $2.66 | $0.97 | ||
| Q2 24 | $4.00 | $97.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.4B | — |
| 总债务越低越好 | — | $277.8M |
| 股东权益账面价值 | $18.7B | $2.3B |
| 总资产 | $29.5B | $4.5B |
| 负债/权益比越低杠杆越低 | — | 0.12× |
8季度趋势，按日历期对齐
现金及短期投资BIIBRUSHA
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | $212.6M | ||
| Q3 25 | — | $242.0M | ||
| Q2 25 | — | $211.1M | ||
| Q1 25 | — | $228.7M | ||
| Q4 24 | — | $228.1M | ||
| Q3 24 | — | $185.1M | ||
| Q2 24 | — | $167.3M |
总债务BIIBRUSHA
| Q1 26 | — | $277.8M | ||
| Q4 25 | $6.3B | $274.8M | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | $408.4M | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — |
股东权益BIIBRUSHA
| Q1 26 | $18.7B | $2.3B | ||
| Q4 25 | $18.3B | $2.2B | ||
| Q3 25 | $18.2B | $2.2B | ||
| Q2 25 | $17.6B | $2.2B | ||
| Q1 25 | $17.0B | $2.2B | ||
| Q4 24 | $16.7B | $2.1B | ||
| Q3 24 | $16.4B | $2.1B | ||
| Q2 24 | $15.9B | $2.0B |
总资产BIIBRUSHA
| Q1 26 | $29.5B | $4.5B | ||
| Q4 25 | $29.4B | $4.4B | ||
| Q3 25 | $29.2B | $4.6B | ||
| Q2 25 | $28.3B | $4.7B | ||
| Q1 25 | $28.0B | $4.7B | ||
| Q4 24 | $28.0B | $4.6B | ||
| Q3 24 | $28.3B | $4.6B | ||
| Q2 24 | $26.8B | $4.5B |
负债/权益比BIIBRUSHA
| Q1 26 | — | 0.12× | ||
| Q4 25 | 0.34× | 0.12× | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | 0.19× | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | $594.3M | $411.6M |
| 自由现金流率自由现金流/营收 | 24.0% | 24.4% |
| 资本支出强度资本支出/营收 | — | 2.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.4B | $828.4M |
8季度趋势，按日历期对齐
经营现金流BIIBRUSHA
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $112.9M | ||
| Q3 25 | $1.3B | $367.8M | ||
| Q2 25 | $160.9M | $227.6M | ||
| Q1 25 | $259.3M | $153.5M | ||
| Q4 24 | $760.9M | $392.3M | ||
| Q3 24 | $935.6M | $111.7M | ||
| Q2 24 | $625.8M | $270.6M |
自由现金流BIIBRUSHA
| Q1 26 | $594.3M | $411.6M | ||
| Q4 25 | $468.0M | $31.9M | ||
| Q3 25 | $1.2B | $271.2M | ||
| Q2 25 | $134.3M | $113.8M | ||
| Q1 25 | $222.2M | $45.1M | ||
| Q4 24 | $721.6M | $263.5M | ||
| Q3 24 | $900.6M | $-20.0M | ||
| Q2 24 | $592.3M | $177.2M |
自由现金流率BIIBRUSHA
| Q1 26 | 24.0% | 24.4% | ||
| Q4 25 | 20.5% | 1.9% | ||
| Q3 25 | 48.4% | 15.2% | ||
| Q2 25 | 5.1% | 6.2% | ||
| Q1 25 | 9.1% | 2.6% | ||
| Q4 24 | 29.4% | 13.7% | ||
| Q3 24 | 36.5% | -1.1% | ||
| Q2 24 | 24.0% | 9.1% |
资本支出强度BIIBRUSHA
| Q1 26 | — | 2.0% | ||
| Q4 25 | 1.9% | 4.8% | ||
| Q3 25 | 1.8% | 5.4% | ||
| Q2 25 | 1.0% | 6.2% | ||
| Q1 25 | 1.5% | 6.2% | ||
| Q4 24 | 1.6% | 6.7% | ||
| Q3 24 | 1.4% | 7.3% | ||
| Q2 24 | 1.4% | 4.8% |
现金转化率BIIBRUSHA
| Q1 26 | — | — | ||
| Q4 25 | — | 1.75× | ||
| Q3 25 | 2.73× | 5.51× | ||
| Q2 25 | 0.25× | 3.14× | ||
| Q1 25 | 1.08× | 2.55× | ||
| Q4 24 | 2.85× | 5.25× | ||
| Q3 24 | 2.41× | 1.41× | ||
| Q2 24 | 1.07× | 3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
RUSHA
| New and used commercial vehicle sales | $955.1M | 57% |
| Aftermarket products and services sales | $627.2M | 37% |
| Lease and rental sales | $92.3M | 5% |
| Finance and insurance | $5.6M | 0% |
